[go: up one dir, main page]

Hara et al., 2016 - Google Patents

Kawasaki disease: a matter of innate immunity

Hara et al., 2016

View HTML
Document ID
12245975810632189239
Author
Hara T
Nakashima Y
Sakai Y
Nishio H
Motomura Y
Yamasaki S
Publication year
Publication venue
Clinical & Experimental Immunology

External Links

Snippet

Kawasaki disease (KD) is an acute systemic vasculitis of childhood that does not have a known cause or aetiology. The epidemiological features (existence of epidemics, community outbreaks and seasonality), unique age distribution and clinical symptoms and signs of KD …
Continue reading at academic.oup.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes

Similar Documents

Publication Publication Date Title
Hara et al. Kawasaki disease: a matter of innate immunity
Wang et al. Liver immune profiling reveals pathogenesis and therapeutics for biliary atresia
Vojdani et al. Persistent SARS-CoV-2 infection, EBV, HHV-6 and other factors may contribute to inflammation and autoimmunity in long COVID
Frasca et al. B cell immunosenescence
Bank The role of gamma delta T cells in autoimmune rheumatic diseases
Shafqat et al. How neutrophils shape the immune response: reassessing their multifaceted role in health and disease
de Cevins et al. A monocyte/dendritic cell molecular signature of SARS-CoV-2-related multisystem inflammatory syndrome in children with severe myocarditis
Schirmer et al. Linking the human gut microbiome to inflammatory cytokine production capacity
Nagata Causes of Kawasaki disease—from past to present
Kaneko et al. Our evolving understanding of Kawasaki disease pathogenesis: role of the gut microbiota
Brodin et al. Human immune system variation
Esposito et al. The gut microbiota-host partnership as a potential driver of Kawasaki syndrome
Lucchino et al. Mucosa–Environment interactions in the pathogenesis of rheumatoid arthritis
Pieniawska-Śmiech et al. Diagnostic challenges in patients with inborn errors of immunity with different manifestations of immune dysregulation
Nahum et al. Defining the biological responses of IL-6 by the study of a novel IL-6 receptor chain immunodeficiency
Chen et al. Commensal microbe-specific activation of B2 cell subsets contributes to atherosclerosis development independently of lipid metabolism
Gibson et al. Keeping the bowel regular: the emerging role of Treg as a therapeutic target in inflammatory bowel disease
Cichon et al. Scrutinizing mechanisms of the ‘Obesity paradox in sepsis’: obesity is accompanied by diminished formation of neutrophil extracellular traps (NETs) due to restricted neutrophil–platelet interactions
Schoffelen et al. Genetic variation in pattern recognition receptors and adaptor proteins associated with development of chronic Q fever
Nikolakis et al. The role of the lymphatic system in the pathogenesis and treatment of inflammatory bowel disease
Arleevskaya et al. A transient peak of infections during onset of rheumatoid arthritis: a 10-year prospective cohort study
Gülden et al. Microbiota control immune regulation in humanized mice
Tomasik et al. Inflammasomes—new contributors to blood diseases
Koh et al. Cytokine networks as targets for preventing and controlling Chagas heart disease
Fettig et al. Inhibition of Th1 activation and differentiation by dietary guar gum ameliorates experimental autoimmune encephalomyelitis